CJC-1295 (No DAC), Ipamorelin, GHRP-2
Also known as No DAC, CJC-1295 (No DAC), CJC-1295 without DAC, Mod GRF (1-29)
This triple peptide blend—CJC-1295 (No DAC), Ipamorelin, and GHRP-2—represents a premium growth hormone optimizer that multiplies natural GH release through three complementary pathways for superior muscle building, fat metabolism, and recovery. CJC-1295 triggers the main GH pulse like your body’s sleep signal, Ipamorelin provides clean, selective GH stimulation without hunger or prolactin spikes, and GHRP-2 adds extra amplification for even higher peaks.
Route
Subcutaneous injection
Dose range
100 mcg – 600 mcg
Frequency
1–2 times per day
Cycle length
12–16 weeks
Overview
This triple peptide blend—CJC-1295 (No DAC), Ipamorelin, and GHRP-2—represents a premium growth hormone optimizer that multiplies natural GH release through three complementary pathways for superior muscle building, fat metabolism, and recovery. CJC-1295 triggers the main GH pulse like your body’s sleep signal, Ipamorelin provides clean, selective GH stimulation without hunger or prolactin spikes, and GHRP-2 adds extra amplification for even higher peaks. Together, they can elevate GH and IGF-1 levels 5-10 times baseline, creating an environment perfect for lean muscle gains, rapid healing, and targeted fat loss while preserving your natural hormone rhythms.
Key benefits include enhanced sleep quality, sharper focus from better brain recovery, stronger bones and joints, and metabolic improvements that help control blood sugar. The blend shines for anti-aging, with users reporting thicker skin, fuller hair, and sustained energy as GH supports collagen and cellular repair. Unlike single peptides, this trio minimizes side effects by balancing stimulation—Ipamorelin’s gentleness offsets GHRP-2’s potency. Ideal for athletes in heavy training phases or middle-aged individuals reversing sarcopenia (muscle wasting), injected nightly or split doses to align with natural GH windows. Research suggests it boosts somatotroph cell activity and GH pulse strength, delivering compounding results over months for body composition transformation and vitality restoration.
Studied benefits
- A "triple-threat" GH secretagogue stack
- It provides a multi-pathway approach to GH release, offering the metabolic benefits of GHRP-2 and the high safety/selectivity profile of Ipamorelin for optimized body composition and recovery
Reported side effects
- Generally well-tolerated, though the GHRP-2 can cause increased hunger
- Mild water retention or tingling in the hands (paresthesia) may occur at higher doses
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
CJC-1295 (No DAC) + Ipamorelin + GHRP-2 Blend
Reconstitute with 3.0 mL bacteriostatic water for accurate low-volume measurement.
Investigate the "triple-threat" approach to growth hormone secretagogues (GHS) for enhanced lean muscle mass and metabolic rate.
| Phase | Total Daily Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Standard | 300 mcg (100mcg each) | 12 units (0.12 mL) | + Log |
| Advanced Research | 600 mcg (200mcg each) | 24 units (0.24 mL) | + Log |
Frequency
1–2 times per day.
Timing
Bedtime or immediately post-workout; must be on an empty stomach.
Cycle length
12–16 weeks.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
16 doses of 300 mcg per vial
At the starting dose (300 mcg × 7/week for a 12-week cycle) you would use about 25.2 mg, i.e. 6 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
This "Triple Stack" requires a high-protein diet to provide the building blocks for substantial tissue repair and metabolic enhancement. Follow a structured exercise routine involving both strength and endurance work to leverage the multi-pathway GH stimulation provided by the different secretagogues. Ensure 7–9 hours of quality sleep to support the intense recovery and fat-burning processes initiated by this blend. Maintain strict fasting for 2 hours prior to administration and 30 minutes after to prevent insulin from interfering with the specific signaling of the pituitary receptors.
Evidence
Research summaries
Growth Hormone Response to GHRP-2 in Metabolic Regulation
Findings: Drastically increases appetite to help "hard gainers" eat enough to grow, while keeping growth hormone levels high.
This "tri-blend" is designed for one main goal: maximum growth. GHRP-2 is famous for mimicking "ghrelin," the hunger hormone. In studies, mice given GHRP-2 didn't just release growth hormone; they also gained significant weight because they ate way more food. By adding Ipamorelin and CJC-1295, the blend aims to keep the growth hormone pulse high and sustained. The CJC acts as the base amplifier, Ipamorelin provides a clean release, and GHRP-2 adds the raw power and appetite stimulation. This is the go-to research stack for situations where "eating enough to recover" is the hardest part of the equation, like in wasting diseases or extreme bulking phases.
Read the study ↗Selectivity and Synergy of GHRH and GHRP Combinations
Findings: Balances the "dirty" power of GHRP-2 with the "clean" safety of Ipamorelin for a broader effect profile.
Why mix three? Science shows that different peptides hit different buttons. CJC-1295 pushes the "GHRH" button. GHRP-2 and Ipamorelin both push the "Ghrelin" button, but they do it differently. GHRP-2 pushes it with a sledgehammer (lots of GH, but also some stress hormones), while Ipamorelin pushes it with a precision finger (pure GH). By blending them, researchers attempt to get the best of both worlds: the high peak of GHRP-2 and the longer, safer tail of Ipamorelin, all amplified by CJC-1295. It’s a "full-spectrum" approach to triggering the pituitary gland to release as much hormone as safely possible.
Read the study ↗Efficacy of Peptide Blends in Sustaining Growth Hormone Levels
Findings: Prevents the "crash" in hormone levels, keeping the body in an anabolic (building) state for longer.
Single peptides often cause a quick spike in hormones that drops off fast. Research on CJC-1295 shows it helps extend this window. When combined with two fast-acting peptides like Ipamorelin and GHRP-2, the CJC-1295 acts like a "time-extender." It primes the pituitary gland so that when the other two peptides hit, the resulting wave of growth hormone is not only higher (taller wave) but also lasts longer (wider wave). This longer exposure to growth hormone is key for repairing tissues like tendons and ligaments that have poor blood flow and need all the help they can get.
Read the study ↗More references (6)
- CJC-1295 and Ipamorelin: Benefits and Safety in 2025
- Targeting IGF-1 to alleviate obesity through energy expenditure, 2025
- Safety of certain bulk drug substances for use in compounding (FDA Report), 2023
- Synergy of GH secretagogues (Ipamorelin & GHRPs) in growth stimulation, 2013
- GHRP-2 and Ipamorelin: Growth hormone release mechanisms, 2011
- Ipamorelin: A selective growth hormone secretagogue, 1998
Identification
Chemistry
- common names
- CJC-1295 (No DAC), CJC-1295 without DAC, Mod GRF (1-29), Modified GHRH (1-29), GRF (1-29) analog, MOD-GRF, pulsatile CJC-1295, CJC-1295 free; Ipamorelin, NNC-26-0161, Growth Hormone Secretagogue, GHS-R1a agonist, selective ghrelin mimetic; GHRP-2, Growth Hormone Releasing Peptide-2, Pralmorelin, GPA-748, KP-102, Met-enkephalin analog; Blend Designation: CJC-1295 (No DAC)/Ipamorelin/GHRP-2 blend, Triple peptide blend, CJC-1295/Ipamorelin/GHRP-2 combination, MOD-GRF/Ipamorelin/GHRP-2 blend, three-component growth hormone secretagogue blend
- cas
- 446036-97-1
- formula
- C₁₅₂H₂₅₂N₄₄O₄₂
- molecular weight
- 3,367.79–3,369.1 Da (g/mol)
- sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
- source
- Synthetic (laboratory-manufactured)
- biosynthesis
- Non-ribosomal synthesis via chemical peptide synthesis
- type
- Linear polypeptide with four amino acid substitutions from naturally occurring GHRH(1-29)
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks
CJC-1295 (No DAC)
No DAC
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 8–12 weeks